JY231 injection for autoimmune diseases
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests a new cell therapy called JY231 for people with certain autoimmune diseases like lupus or Sjögren's syndrome that haven't improved with standard treatments. The goal is to see if it can reduce disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have one of these conditions: lupus, Sjögren's syndrome, scleroderma, dermatomyositis, or vasculitis.
- Your condition is moderate to severe and hasn't responded well to at least 2 standard treatments.
- You haven't had CAR-T cell therapy before.
- You are not pregnant, breastfeeding, or planning pregnancy during the study.
- You do not have active infections or certain blood-borne viruses (like HIV, hepatitis B or C).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new cell therapy called JY231 for people with severe autoimmune diseases like lupus, Sjogren's, scleroderma, dermatomyositis, or ANCA vasculitis that haven't improved with standard treatments. It aims to see if the therapy can help control the disease when other options have failed.
This trial tests a one-time CAR-T cell therapy for people with severe autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, dermatomyositis, or ANCA vasculitis. It aims to reset the immune system and reduce disease activity for those who haven't responded well to standard treatments.
This trial tests an investigational drug called JY231 for people with active systemic lupus erythematosus (SLE) that is not well controlled with standard treatments. The goal is to see if JY231 can reduce lupus activity and improve symptoms.
This trial tests a new injection called JY231 for people with certain hard-to-treat nerve and immune disorders that haven't improved with standard treatments. It aims to see if this experimental therapy can help control the disease when other options have failed.
This trial tests a new treatment, JY231, for people with B-cell blood cancers that have come back or not responded to other treatments. It aims to see if this therapy can help when other options have stopped working.
This trial tests a new treatment, JY231, for people whose B-cell lymphoma has returned or stopped responding to previous therapies. It aims to see if JY231 can help shrink tumors or control the disease.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.